MannKind (MNKD) Posts Q3 Loss of 9c/Share
MannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.09), $0.13 worse than the analyst estimate of $0.04.
Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:
- $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
- $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
- $17.3 million in proceeds from warrant and stock option exercises.
Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:
- $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
- $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
- $17.3 million in proceeds from warrant and stock option exercises.
Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:
- $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
- $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
- $17.3 million in proceeds from warrant and stock option exercises.
Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:
- $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
- $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
- $17.3 million in proceeds from warrant and stock option exercises.
For earnings history and earnings-related data on MannKind (MNKD) click here.